News headlines about Chembio Diagnostics (NASDAQ:CEMI) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chembio Diagnostics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.7408428021996 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Chembio Diagnostics (NASDAQ CEMI) opened at $9.00 on Friday. Chembio Diagnostics has a twelve month low of $5.05 and a twelve month high of $9.20. The company has a market capitalization of $110.87, a price-to-earnings ratio of -15.79 and a beta of 1.24. The company has a quick ratio of 2.19, a current ratio of 3.54 and a debt-to-equity ratio of 0.01.
COPYRIGHT VIOLATION WARNING: This piece was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-chembio-diagnostics-cemi-share-price.html.
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.